Zacks Research Has Positive Outlook for ENSC Q3 Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Investment analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for shares of Ensysce Biosciences in a research report issued to clients and investors on Tuesday, July 14th. Zacks Research analyst B. Sorensen now expects that the company will earn $0.09 per share for the quarter, up from their prior estimate of ($0.49). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.53) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($1.53) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Ensysce Biosciences Price Performance

NASDAQ:ENSC opened at $0.28 on Friday. The company has a market capitalization of $4.35 million, a PE ratio of -0.08 and a beta of 0.78. Ensysce Biosciences has a 1-year low of $0.23 and a 1-year high of $2.75. The firm’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.49.

Ensysce Biosciences (NASDAQ:ENSC) last announced its earnings results on Friday, May 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.21. The firm had revenue of $0.96 million during the quarter, compared to analyst estimates of $1.00 million. Ensysce Biosciences had a negative return on equity of 766.45% and a negative net margin of 250.39%.

Institutional Investors Weigh In On Ensysce Biosciences

Several large investors have recently bought and sold shares of ENSC. Virtu Financial LLC purchased a new position in Ensysce Biosciences in the 3rd quarter worth about $34,000. Citadel Advisors LLC purchased a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at about $34,000. DRW Securities LLC raised its holdings in shares of Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares during the last quarter. 5.63% of the stock is currently owned by institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.